Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8940765 | European Urology Oncology | 2018 | 16 Pages |
Abstract
Two ways to potentially improve outcomes following salvage radiotherapy for prostate cancer that recurs after prostatectomy are to start treatment at a lower prostate-specific antigen level and to use concurrent hormonal therapy. Our review suggests that the available evidence is imperfect, but highlights that both measures are likely to improve clinical outcomes in general, but perhaps not uniformly and/or consistently for all patients. Physician-patient shared decision-making and further research are critical.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Amar U. Kishan, Rahul D. Tendulkar, Phuoc T. Tran, Christopher C. Parker, Paul L. Nguyen, Andrew J. Stephenson, Christian Carrie,